Azo reductase-responsive etoposide self-assembled nanofiber polypeptide, and preparation method and application thereof
By designing the self-assembled nanofiber peptide of azoreductase-responsive etoposide nanofiber polypeptide, using alkaline phosphatase to catalyze the formation of nanofibers, releasing etoposide in hypoxic tumor cells, solving the problems of poor water solubility and toxic side effects of etoposide , significantly improves the tumor treatment effect.
Patent Information
- Application Number
- CN202411220149.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-02
- Publication Date
- 2024-12-03
AI Technical Summary
The poor water solubility of etoposide and the toxic side effects in clinical preparations are difficult to achieve specific release of existing nanoparticles or nanofiber carriers in tumor tissues, resulting in poor treatment effect.
A kind of azoreductase-responsive etoposide self-assembled nanofiber polypeptide was designed, and the short peptide Nap-GFFpYE(Azo)-N3 was connected to etoposide, and the nanofiber catalyzed catalyzed by alkaline phosphatase was used to form nanofibers. Free etoposide is released under the action of azoreductase in oxygen tumor cells to improve the therapeutic effect.
The concentration of etoposide in hypoxic tumor cells has been significantly improved, and the therapeutic effect on tumors has been enhanced. The nanofiber has good biocompatibility and three-dimensional morphology, which can easily enter tumor cells and reduce toxic side effects.
Smart Images

Figure BDA0005022792780000021 
Figure BDA0005022792780000031 
Figure BDA0005022792780000032
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomedicine, and in particular relates to an azoreductase-responsive etoposide self-assembly nanofiber polypeptide, a preparation method and an application thereof. Background Art
[0002] Etoposide is a broad-spectrum anticancer drug used in the clinical treatment of tumors. Due to its poor water solubility, the etoposide preparations currently used in clinical practice mostly use polysorbate-80, polyethylene glycol-400, benzyl alcohol, citric acid and anhydrous ethanol as a solvent. Dilute to the final concentration with saline or glucose before administration. These solvents can cause a variety of adverse reactions, including allergic reactions and neurotoxicity.
[0003] In order to solve the poor water solubility of etoposide and the toxic and side effects of clinical preparations, it is now generally believed that nanoparticles have potential application prospects as drug carriers. Nanoparticles or nanofibers as drug delivery systems can prolong the drug action time and enhance the efficacy, reduce toxic and side effects, control drug release, and improve the solubility of poorly soluble drugs. In addition, the targeting of carriers or nano drug particles can be improved by modifying nanoparticles or nanofibers, such as connecting targeting groups such as folic acid and transferrin, thereby avoiding the non-specific release of drugs in tissues. Nanoparticles or nanofibers formed by small molecule self-assembly have received widespread attention in recent years, especially the self-assembly of small molecule polypeptides, because they have good biocompatibility, are non-toxic to the body, and are easy to synthesize. As a new type of material, small molecule hydrogels have been widely studied by scientists at home and abroad in biomedicine and biomaterials due to their good biocompatibility and good three-dimensional morphology.
[0004] So far, we have designed a carboxylesterase-mediated release system of etoposide nanofibers. However, since carboxylesterase is expressed in various cells, it cannot specifically release etoposide in tumor tissues. Therefore, we redesigned an etoposide self-assembly system that responds to azoreductase in a hypoxic microenvironment, which can specifically release etoposide in tumor hypoxic tissues to enhance the therapeutic effect of etoposide on tumors. Summary of the invention
[0005] In view of this, in order to solve the above technical problems, the present invention proposes an azoreductase-responsive etoposide self-assembling nanofiber polypeptide, and proposes a preparation method and application thereof, wherein a small molecule polypeptide compound of Nap-GFFpYE(Azo)-Etoposide is formed by connecting a self-assembling short peptide Nap-GFFpYE(Azo)-N3 with a hydrophobic drug etoposide, and self-assembly is formed into nanofibers by alkaline phosphatase catalysis. The nanofibers can enter cells in the form of endocytosis, and release free etoposide original drug under the action of azoreductase in hypoxic tumor cells, thereby significantly increasing the concentration of etoposide in hypoxic tumor cells and enhancing the therapeutic effect of etoposide on tumors.
[0006] To achieve the above object, the technical solution of the present invention is achieved as follows:
[0007] An azoreductase-responsive etoposide self-assembling nanofiber polypeptide, the polypeptide is Nap-GFFpYE (Azo) -Etoposide, including Nap-GFFpYE (Azo) -Etoposide1, Nap-GFFpYE (Azo) -Etoposide2 and Nap-GFFpYE (Azo) -Etoposide3;
[0008] The structural formula of the Nap-GFFpYE(Azo)-Etoposide1 is:
[0009]
[0010] The structural formula of the Nap-GFFpYE(Azo)-Etoposide2 is:
[0011]
[0012] The structural formula of the Nap-GFFpYE(Azo)-Etoposide3 is:
[0013]
[0014] In some preferred azoreductase-responsive etoposide self-assembling nanofiber polypeptide embodiments of the present invention, the Nap-GFFpYE(Azo)-Etoposide is obtained by a Click reaction between Nap-GFFpYE(Azo)-N3 and an etoposide alkynyl derivative;
[0015] The structural formulas of the three etoposide alkynyl derivatives -Etoposide1, -Etoposide2 and -Etoposide3 in Nap-GFFpYE(Azo)-Etoposide are:
[0016]
[0017] The N-terminus of the polypeptide Nap-GFFpYE(Azo)-Etoposide is a short peptide Nap-GFFpYE(Azo)-N3 with enzymatic self-assembly properties. The azide group in the short peptide structure and the alkyne group in the etoposide derivative undergo a click chemical reaction under the catalysis of monovalent copper ions to form an integral molecule, that is, the self-assembled short peptide Nap-GFFpYE(Azo)-N3 is linked to etoposide through an azo bond that can be cleaved under the action of azoreductase.
[0018] The second aspect of the present invention provides a method for preparing the azoreductase-responsive etoposide self-assembling nanofiber polypeptide, comprising the following steps:
[0019] S1. Synthesis of intermediate compound Fmoc-pY-COOH:
[0020] 1) phosphorus pentoxide, phosphoric acid and tyrosine are reacted; after the reaction, water is added and diluted with n-butanol, a white solid is precipitated at low temperature, and after filtering, precipitation, washing and drying, phosphorylated tyrosine is obtained;
[0021] 2) dissolving the phosphorylated tyrosine in a saturated sodium bicarbonate solution, adding Fmoc-OSU dissolved in a solvent to react, removing the solvent, adding hydrochloric acid, extracting with ethyl acetate, collecting the ethyl acetate layer, adding anhydrous sodium sulfate to dry, and removing the ethyl acetate to obtain Fmoc-phosphorylated tyrosine;
[0022] S2. Solid phase synthesis of Nap-GFFpYE(Azo)-N3:
[0023] 1) Connecting Fmoc-Glu(N3)-COOH to a solid phase carrier 2-chlorotrityl chloride resin in a solid phase synthesizer, and using dichloromethane as a solvent for the reaction;
[0024] 2) using a piperidine N,N-dimethylformamide solution to remove the protective group Fmoc, taking the polypeptide condensation agent HBTU and placing it in the solid phase synthesizer of step 1), and sequentially adding Fmoc-pY-OH, Fmoc-F-OH, Fmoc-F-OH, and Fmoc-G-OH, and blocking the N-terminus of the short peptide with naphthaleneacetic acid to obtain a self-assembling short peptide Nap-GFFpYE(Azo)-N3;
[0025] 3) using a cutting solution, trifluoroacetic acid, to remove the prepared short peptide from the resin, and separating the resulting Nap-GFFpYE(Azo)-N3 using a high performance liquid chromatography;
[0026] S3. Synthesis of Nap-GFFpYE(Azo)-Etoposide 1, Nap-GFFpYE(Azo)-Etoposide 2, Nap-GFFpYE(Azo)-Etoposide3:
[0027] 1) dissolving etoposide in N,N-dimethylformamide solution, adding (E)-4-nitrophenyl(4-((4-(prop-2-yn-1-yloxy)phenyl)diazenyl)benzyl)carbonate, and purifying to obtain three alkynyl-modified derivatives of etoposide, Etoposide1, Etoposide2 and Etoposide3;
[0028] 2) Three alkynyl-modified derivatives of etoposide were reacted with the self-assembling polypeptide Nap-GFFpYE(Azo)-N3 synthesized in a monovalent copper ion solution, respectively. After the reaction, high-performance liquid phase separation was performed to obtain azoreductase-responsive etoposide nanofiber polypeptides Nap-GFFpYE(Azo)-Etoposide1, Nap-GFFpYE(Azo)-Etoposide2 and Nap-GFFpYE(Azo)-Etoposide3.
[0029] The third aspect of the present invention provides the use of the azoreductase-responsive etoposide self-assembling nanofiber polypeptide in the preparation of a small molecule hydrogel nanofiber transport system, wherein the small molecule compound Nap-GFFpYE (Azo) -Etoposide1 forms nanofibers by self-assembling in a PBS solution of alkaline phosphatase or by self-assembling under the catalysis of alkaline phosphatase highly expressed on the cell membrane surface.
[0030] The small molecule compound Nap-GFFpYE(Azo)-Etoposide2 forms nanofibers by self-assembling in a PBS solution of alkaline phosphatase or by self-assembling under the catalysis of alkaline phosphatase highly expressed on the cell membrane surface.
[0031] The small molecule compound Nap-GFFpYE(Azo)-Etoposide3 forms nanofibers by self-assembling in a PBS solution of alkaline phosphatase or by self-assembling under the catalysis of alkaline phosphatase highly expressed on the cell membrane surface.
[0032] In some preferred embodiments of the present invention of the use of the azoreductase-responsive etoposide self-assembling nanofiber polypeptide in the preparation of a small molecule hydrogel nanofiber delivery system, the self-assembled nanofibers enter the cells by endocytosis.
[0033] It should be noted that the amino acids used in the present invention are all pure natural amino acids with L configuration.
[0034] Compared with the prior art, the azoreductase-responsive etoposide self-assembling nanofiber polypeptide, preparation method and application of the present invention have the following advantages:
[0035] (1) The azoreductase-responsive etoposide self-assembling nanofiber polypeptide Nap-GFFpYE(Azo)-Etoposide (including Nap-GFFpYE(Azo)-Etoposide1, Nap-GFFpYE(Azo)-Etoposide2, and Nap-GFFpYE(Azo)-Etoposide3) of the present invention is formed by connecting the self-assembling small molecule polypeptide Nap-GFFpYE(Azo)-N3 with the hydrophobic drug etoposide, and self-assembling to form a nanohydrogel (nanofibers) under the catalysis of alkaline phosphatase in vitro or alkaline phosphatase on the cell membrane surface. The nanofibers can enter the cell in the form of endocytosis, and release free etoposide original drug under the action of azoreductase in hypoxic tumor cells, thereby significantly increasing the concentration of etoposide in hypoxic tumor cells and enhancing the therapeutic effect of etoposide on lung cancer;
[0036] (2) In the preparation process of the azoreductase-responsive etoposide self-assembling nanofiber polypeptide Nap-GFFpYE (Azo) -Etoposide of the present invention, the raw materials used are various amino acids required for daily culture of cells, which have no toxic side effects on cells, and the prepared self-assembling polypeptide carrier Nap-GFFpYE (Azo) -N3 has no obvious inhibitory effect on cell growth;
[0037] (3) The nano-hydrogel prepared by the present invention has good biocompatibility and good three-dimensional morphology (nanofibers of about 10 nanometers), can more easily enter tumor cells, and has broad application prospects in biomaterial drug delivery. BRIEF DESCRIPTION OF THE DRAWINGS
[0038] Figure 1 The synthetic route of Fmoc-pY-COOH described in Example 1 of the present invention;
[0039] Figure 2 The synthetic route of Nap-GFFpYE(Azo)-N3 described in Example 2 of the present invention;
[0040] Figure 3The synthetic route of Nap-GFFpYE(Azo)-Etoposide1, Nap-GFFpYE(Azo)-Etoposide2 and Nap-GFFpYE(Azo)-Etoposide3 described in Example 3 of the present invention;
[0041] Figure 4 This is the hydrogen spectrum of Nap-GFFpYE(Azo)-Etoposide1 described in Example 3 of the present invention;
[0042] Figure 5 This is the hydrogen spectrum of Nap-GFFpYE(Azo)-Etoposide2 described in Example 3 of the present invention;
[0043] Figure 6 This is the hydrogen spectrum of Nap-GFFpYE(Azo)-Etoposide3 described in Example 3 of the present invention;
[0044] Figure 7 The three-dimensional morphology images of the three small molecule hydrogels formed by Nap-GFFpYE(Azo)-Etoposide1, Nap-GFFpYE(Azo)-Etoposide2 and Nap-GFFpYE(Azo)-Etoposide3 described in Example 4 of the present invention observed under transmission electron microscopy;
[0045] Figure 8 The inhibition of LLC and A549 cells under normoxic and hypoxic conditions by etoposide, Nap-GFFpYE(Azo)-Etoposide1, Nap-GFFpYE(Azo)-Etoposide2 and Nap-GFFpYE(Azo)-Etoposide3 in Experimental Example 1;
[0046] Fig. 9The treatment of mouse lung cancer LLC tumor cells by Nap-GFFpYE(Azo)-Etoposide1, Nap-GFFpYE(Azo)-Etoposide2 and Nap-GFFpYK-Etoposide3 in Experimental Example 2; in the figure, PBS represents the PBS group, NF represents the Nap-GFFpYE(Azo)-N3 group, Etoposide represents the etoposide group, Etoposide+NF represents the Nap-GFFpYE(Azo)-N3+etoposide group, NFE represents the (Azo)-1 represents the Nap-GFFPYK-Etoposide1 group, NFE(Azo)-2 represents the Nap-GFFPYK-Etoposide2 group, and NFE(Azo)-3 represents the Nap-GFFPYK-Etoposide3 group; Figure (A) is a linear graph showing the changes in tumor volume over time of administration (1 to 14 days); Figure (B) is a linear graph showing the changes in mouse body weight over time of administration (1 to 14 days); Figure (C) is a physical graph showing the tumor volume on the 14th day; and Figure (D) is a bar graph showing the tumor weight on the 14th day. DETAILED DESCRIPTION
[0047] Unless otherwise defined, the technical terms used in the following examples have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. The test reagents used in the following examples, unless otherwise specified, are all conventional biochemical reagents; the experimental methods, unless otherwise specified, are all conventional methods.
[0048] The present invention will be described in detail below with reference to the embodiments and the accompanying drawings.
[0049] Example 1 Synthesis of Fmoc-pY-COOH
[0050] 1) Weigh phosphorus pentoxide (P2O5, 10 g, 70.4 mmol), add 85% phosphoric acid (H3PO4, 13.0 g) into a three-way flask, heat and stir in an 80°C oil bath until almost completely mixed; then add 3.22 g of tyrosine (17.8 mmol) into the system, protect with nitrogen to prevent contact with moisture in the air, and react at 80°C for 24 hours to obtain a dark brown viscous liquid, then add 30 ml of water, continue heating for 30 minutes, cool to room temperature, dilute with 650 ml of n-butanol, keep at 0°C for 3 hours, a white solid precipitates, filter the precipitate, wash twice with 20 ml of ice water, 20 ml of ethanol, and 20 ml of ether each time; put it in a vacuum drying oven and dry it for 5 hours to obtain phosphotyrosine;
[0051] 2) Weigh 2.62 g (10 mmol) of phosphotyrosine and dissolve it in 20 ml of saturated sodium bicarbonate solution. Weigh 3.38 g (10 mmol) of Fmoc-OSU and dissolve it in 20 ml of acetonitrile solution. Slowly add it dropwise to the previous solution and react for 12 h. Remove acetonitrile by rotary evaporation. Add 150 ml of 1 mol / L hydrochloric acid and extract three times with 200 ml of ethyl acetate. Collect the ethyl acetate layer, add anhydrous sodium sulfate and dry it for 3 h. Remove ethyl acetate by rotary evaporation to obtain Fmoc-phosphorylated tyrosine (Fmoc-pY-COOH).
[0052] The synthesis steps of this example refer to Figure 1 .
[0053] Example 2 Synthesis of Nap-GFFpYE(Azo)-N3
[0054] Nap-GFFpYE(Azo)-N3 was synthesized by solid phase synthesis. The specific synthesis steps are as follows:
[0055] 1) Weigh 0.75mmol (700mg) of dichlororesin, add it to the solid phase synthesizer, add 20ml of dichloromethane (DCM) to immerse the resin, swell the resin for 20 minutes, remove the DCM solvent, add 1mmol (469mg) of Fmoc-Glu (N3) -COOH in DCM solution, add 800μl of N, N-diisopropylethylamine (DIPEA), react for 2h, then wash five times with DCM, 2min each time; use a blocking solution with a volume ratio of DCM: methanol: DIPEA = 17:2:1, block for 30min; use 20ml of DCM solution each time, wash 5 times, 1min each time; use 20ml of DMF solution each time, wash 5 times, 2min each time; then add 20ml of 20% piperidine in DMF solution, react for 30min, remove the Fmoc protecting group, and expose the amino group for the next reaction;
[0056] 2) Add 1mmol Fmoc-pY-OH (484mg), 1ml DIPEA, 1mmol polypeptide condensation agent HBTU (380mg), react for 2h, wash 5 times with 20ml dimethylformamide (DMF) solution, 2min each time; add 20ml DMF solution containing 20% piperidine, react for 30min, remove Fmoc protecting group, and expose amino group for next reaction;
[0057] 3) Repeat the experimental step 2), only need to change the Fmoc-protected amino acid added each time, the order of the amino acids added is: Fmoc-F-OH, Fmoc-F-OH, Fmoc-G-OH; the amino acids are linked to the resin in sequence; the last capping group added is: naphthylacetic acid;
[0058] 4) After the reaction is completed, wash with 20 ml of DMF solution for 5 times, 2 min each time; wash with 20 ml of DCM solution for 5 times, 1 min each time; cut with 95% TFA (TFA: H2O: TIS = 95%: 2.5%: 2.5%) for 1 h, wash twice with 20 ml of 1% trifluoroacetic acid (TFA) in dichloromethane solution, collect the total cutting liquid, remove the liquid by rotary evaporation, and separate by high performance liquid phase to obtain the polypeptide compound Nap-GFFpYE(Azo)-N3.
[0059] The synthesis steps of this example refer to Figure 2 .
[0060] Example 3 Synthesis of Nap-GFFpYE(Azo)-Etoposide1, Nap-GFFpYE(Azo)-Etoposide2 and Nap-GFFpYE(Azo)-Etoposide3
[0061] 1) Add 1 mmol of etoposide (484 mg), 1 mmol of compound (E)-4-nitrophenyl(4-((4-(prop-2-yn-1-yloxy)phenyl)diazenyl)benzyl)carbonate (431 mg), 100 μ of DIPEA, and 1 mg of 4-dimethylaminopyridine in N,N-dimethylformamide solution, react for 12 hours, and adjust the pH value to less than 7 with trifluoroacetic acid; then purify by HPLC to obtain three alkynyl derivatives of etoposide (Etoposide1, Etoposide2 and Etoposide3);
[0062] 2) Take 0.05 mmol (86.6 mg) of Etoposide 1, Etoposide 2 and Etoposide 3 respectively, and then react with 0.05 mmol (94.2 mg) of Nap-GFFpYE (Azo) -N3 in 3 ml of dimethylformamide solution under the condition of monovalent copper ion for 2 h, then adjust the pH value to less than 7 with trifluoroacetic acid, and then purify by HPLC to obtain Nap-GFFpYE (Azo) -Etoposide 1, Nap-GFFpYE (Azo) -Etoposide 2 and Nap-GFFpYE (Azo) -Etoposide 3.
[0063] The synthesis steps of this example refer to Figure 3 .
[0064] The hydrogen spectrum of the prepared Nap-GFFpYE(Azo)-Etoposide1 is shown in Figure 2. Figure 4; Reference to the hydrogen spectrum of Nap-GFFpYE(Azo)-Etoposide2 Figure 5 ; Reference to the hydrogen spectrum of Nap-GFFpYE(Azo)-Etoposide3 Figure 6 .
[0065] Example 4 Formation of Nap-GFFpYE(Azo)-Etoposide1, Nap-GFFpYE(Azo)-Etoposide2 and Nap-GFFpYE(Azo)-Etoposide3 Nanofibers
[0066] The steps for forming small molecule hydrogel nanofibers are as follows:
[0067] 1) Weigh 2.00 mg of Nap-GFFpYE(Azo)-Etoposide1, Nap-GFFpYE(Azo)-Etoposide2 and Nap-GFFpYE(Azo)-Etoposide3, respectively, add 1 ml of PBS (pH=7.4 buffer) and adjust the pH to 7.4 with sodium carbonate to obtain a transparent solution; then add alkaline phosphatase (ALP) solution (the final concentration of the enzyme is 2.0 U / ml), respectively. After standing overnight, invert the vial to see a jelly-like colloid, which is the small molecule hydrogel nanofibers of Nap-GFFpYE(Azo)-Etoposide1, Nap-GFFpYE(Azo)-Etoposide2 and Nap-GFFpYE(Azo)-Etoposide3.
[0068] 2) Use a pipette to take about 15 μl of the colloid and drop it onto a clean silicon wafer. Spin coat the colloid to make it evenly distributed on the silicon wafer. Use a transmission electron microscope to observe the morphology. Figure 7 As shown, the morphologies of the three small molecule hydrogels obtained are all uniformly dispersed nanofibers of about 10 nm.
[0069] Experimental Example 1 Inhibition of Nap-GFFpYE(Azo)-Etoposide1, Nap-GFFpYE(Azo)-Etoposide2 and Nap-GFFpYE(Azo)-Etoposide3 on LLC and A549 cells under normoxic and hypoxic conditions
[0070] In order to observe the inhibitory effects of Nap-GFFpYE(Azo)-Etoposide1, Nap-GFFpYE(Azo)-Etoposide2 and Nap-GFFpYE(Azo)-Etoposide3 on tumor cells, we selected LLC and A549 cells in logarithmic growth phase and evenly plated them into 96-well plates, with 5.0×10 cells per well. 3 After 6 h of cell adhesion, etoposide, Nap-GFFpYE(Azo)-Etoposide1[NFE(Azo)-1], Nap-GFFpYE(Azo)-Etoposide2[NFE(Azo)-2], and Nap-GFFpYE(Azo)-Etoposide3[NFE(Azo)-3] were added, and isocratic dilutions (80μmol / L, 40μmol / L, 20μmol / L, 10μmol / L, 5μmol / L, 2.5μmol / L, 1.25μm The cells were cultured in a 37°C cell culture incubator for 48 h. The MTT method was used to detect the inhibitory effects of etoposide, Nap-GFFpYE(Azo)-Etoposide1[NFE(Azo)-1], Nap-GFFpYE(Azo)-Etoposide2[NFE(Azo)-2], and Nap-GFFpYE(Azo)-Etoposide3[NFE(Azo)-3] on different tumor cells. The results are shown in Table 1. Figure 8 As shown in Figure 2, the drug activity of the prepared etoposide nanofibers was significantly improved compared with that of pure etoposide. Under hypoxic conditions, the IC 50 The value increased by 9.76 times, and the IC 50 The value was increased by 10.15 times, and compared with the original drug of etoposide, it had a better effect in hypoxic tumor cells; however, there was no significant difference among the three prepared etoposide nanofiber polypeptide molecules, because the mechanism of self-assembly of etoposide precursor drugs into nanofibers and the release mechanism of etoposide by azoreductase cleavage were the same, so they showed similar biological activities.
[0071] Experimental Example 2 Inhibition of LLC tumor growth by Nap-GFFpYE(Azo)-Etoposide1, Nap-GFFpYE(Azo)-Etoposide2 and Nap-GFFpYE(Azo)-Etoposide3 in a mouse LLC tumor model
[0072] Since the IC values of Nap-GFFpYE(Azo)-Etoposide1, Nap-GFFpYE(Azo)-Etoposide2 and Nap-GFFpYE(Azo)-Etoposide3 on LLC cells were 50 The value increased by 9.76 times. We subcutaneously inoculated mouse LLC cells in C57 mice and observed the growth inhibition of LLC tumors by etoposide nanofiber polypeptide molecules alone in the mouse model.
[0073] Forty-two healthy female C57 mice, aged 6 to 8 weeks, weighing about 20 grams were prepared and randomly divided into 7 groups (PBS group, Nap-GFFpYE(Azo)-N3 group, etoposide group, Nap-GFFpYE(Azo)-N3+etoposide group, Nap-GFFpYE(Azo)-Etoposide1[NFE(Azo)-1] group, Nap-GFFpYE(Azo)-Etoposide2[NFE(Azo)-2] group and Nap-GFFpYE(Azo)-Etoposide3[NFE(Azo)-3] group) with 6 mice in each group. LLC cells in the logarithmic phase were obtained and the cell count was prepared into 1.0×10 6 Each mouse was subcutaneously injected with 200 μl LLC cell suspension, that is, the number of cells injected into each C57 mouse was 2.0×10 5 cells; after subcutaneous injection of LLC cells, the mice's diet and the growth of the tumor at the inoculation site were observed every day, including the time of tumor appearance, tumor volume, and changes in tumor weight; drug administration: the etoposide administration concentration was 5 mg / kg, and the Nap-GFFpYE(Azo)-Etoposide1[NFE(Azo)-1] group, the Nap-GFFpYE(Azo)-Etoposide2[NFE(Azo)-2] group and the Nap-GFFpYE(Azo)-Etoposide The dosage of the two groups (NFE(Azo)-3[NFE(Azo)-3] group) was 14.5 mg / kg, and the mice were injected into the tail vein. After 16 days of continuous administration, no mice died. The Nap-GFFpYE(Azo)-Etoposide1[NFE(Azo)-1] group, the Nap-GFFpYE(Azo)-Etoposide2[NFE(Azo)-2] group, and the Nap-GFFpYE(Azo)-Etoposide3[NFE(Azo)-3] group) had the best tumor inhibition effect. The changes are shown in Fig. 9 shown.
[0074] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. Azoreductase-responsive etoposide self-assembling nanofiber polypeptide, characterized in that: The polypeptide is Nap-GFFpYE(Azo)-Etoposide, including Nap-GFFpYE(Azo)-Etoposide1, Nap-GFFpYE(Azo)-Etoposide2 and Nap-GFFpYE(Azo)-Etoposide3; The structural formula of Nap-GFFpYE(Azo)-Etoposide1 is: The structural formula of the Nap-GFFpYE(Azo)-Etoposide2 is: The structural formula of the Nap-GFFpYE(Azo)-Etoposide3 is:
2. The azoreductase-responsive etoposide self-assembling nanofiber polypeptide according to claim 1, characterized in that: Nap-GFFpYE(Azo)-Etoposide is obtained by click reaction of Nap-GFFpYE(Azo)-N3 and etoposide alkynyl derivative; The structural formulas of the three etoposide alkynyl derivatives -Etoposide1, -Etoposide2 and -Etoposide3 in Nap-GFFpYE(Azo)-Etoposide are:
3. The method for preparing the azoreductase-responsive etoposide self-assembling nanofiber polypeptide according to claim 1 or 2, characterized in that: The steps include: S1. Synthesis of intermediate compound Fmoc-pY-COOH: 1) phosphorus pentoxide, phosphoric acid and tyrosine are reacted; after the reaction, water is added and diluted with n-butanol, a white solid is precipitated at low temperature, and after filtering, precipitation, washing and drying, phosphorylated tyrosine is obtained; 2) dissolving the phosphorylated tyrosine in a saturated sodium bicarbonate solution, adding Fmoc-OSU dissolved in a solvent to react, removing the solvent, adding hydrochloric acid, extracting with ethyl acetate, collecting the ethyl acetate layer, adding anhydrous sodium sulfate to dry, and removing the ethyl acetate to obtain Fmoc-phosphorylated tyrosine; S2. Solid phase synthesis of Nap-GFFpYE(Azo)-N3: 1) Connecting Fmoc-Glu(N3)-COOH to a solid phase carrier 2-chlorotrityl chloride resin in a solid phase synthesizer, and using dichloromethane as a solvent for the reaction; 2) using a piperidine N,N-dimethylformamide solution to remove the protective group Fmoc, taking the polypeptide condensation agent HBTU and placing it in the solid phase synthesizer of step 1), and sequentially adding Fmoc-pY-OH, Fmoc-F-OH, Fmoc-F-OH, and Fmoc-G-OH, and blocking the N-terminus of the short peptide with naphthaleneacetic acid to obtain a self-assembling short peptide Nap-GFFpYE(Azo)-N3; 3) using a cutting solution to remove the prepared short peptide from the resin, and separating the resulting Nap-GFFpYE(Azo)-N3 using a high performance liquid chromatography; S3. Synthesis of Nap-GFFpYE(Azo)-Etoposide1, Nap-GFFpYE(Azo)-Etoposide2, Nap-GFFpYE(Azo)-Etoposide3: 1) dissolving etoposide in N,N-dimethylformamide solution, adding (E)-4-nitrophenyl(4-((4-(prop-2-yn-1-yloxy)phenyl)diazenyl)benzyl)carbonate, and purifying to obtain three alkynyl-modified derivatives of etoposide, Etoposide1, Etoposide2 and Etoposide3; 2) Three alkynyl-modified derivatives of etoposide were reacted with the self-assembling polypeptide Nap-GFFpYE(Azo)-N3 synthesized in a monovalent copper ion solution, respectively. After the reaction, high-performance liquid phase separation was performed to obtain azoreductase-responsive etoposide nanofiber polypeptides Nap-GFFpYE(Azo)-Etoposide1, Nap-GFFpYE(Azo)-Etoposide2 and Nap-GFFpYE(Azo)-Etoposide3.
4. Use of the azoreductase-responsive etoposide self-assembling nanofiber polypeptide according to claim 1 in the preparation of a small molecule hydrogel nanofiber transport system, characterized in that: The small molecule compound Nap-GFFpYE(Azo)-Etoposide1 forms nanofibers by self-assembling in a PBS solution of alkaline phosphatase or by self-assembling into nanofibers under the catalysis of alkaline phosphatase highly expressed on the cell membrane surface.
5. Use of the azoreductase-responsive etoposide self-assembling nanofiber polypeptide according to claim 1 in the preparation of a small molecule hydrogel nanofiber transport system, characterized in that: The small molecule compound Nap-GFFpYE(Azo)-Etoposide2 forms nanofibers by self-assembling in a PBS solution of alkaline phosphatase or by self-assembling under the catalysis of alkaline phosphatase highly expressed on the cell membrane surface.
6. Use of the azoreductase-responsive etoposide self-assembling nanofiber polypeptide according to claim 1 in the preparation of a small molecule hydrogel nanofiber transport system, characterized in that: The small molecule compound Nap-GFFpYE(Azo)-Etoposide3 forms nanofibers by self-assembling in a PBS solution of alkaline phosphatase or by self-assembling under the catalysis of alkaline phosphatase highly expressed on the cell membrane surface.
7. Use of the azoreductase-responsive etoposide self-assembling nanofiber polypeptide according to claim 4, 5 or 6 in the preparation of a small molecule hydrogel nanofiber transport system, characterized in that: The self-assembled nanofibers enter cells through endocytosis.
